Dr. Vamsi Kota, MD
Claim this profileAugusta University Medical Center
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
8 reported clinical trials
37 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 positive
Philadelphia chromosome positive
t(8;21) negative
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Vamsi Kota, MD is currently running
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
BP1001 + Venetoclax + Decitabine
for Acute Myeloid Leukemia
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.
Recruiting1 award Phase 2
More about Vamsi Kota, MD
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Vamsi Kota, MD has experience with
- Cytarabine
- Methotrexate
- Vincristine Sulfate
- Dexamethasone
- Cyclophosphamide
- Inotuzumab Ozogamicin
Breakdown of trials Vamsi Kota, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Lymphoid Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vamsi Kota, MD specialize in?
Vamsi Kota, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL1 positive patients, or patients who are Philadelphia chromosome positive.
Is Vamsi Kota, MD currently recruiting for clinical trials?
Yes, Vamsi Kota, MD is currently recruiting for 2 clinical trials in Augusta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Vamsi Kota, MD has studied deeply?
Yes, Vamsi Kota, MD has studied treatments such as Cytarabine, Methotrexate, Vincristine Sulfate.
What is the best way to schedule an appointment with Vamsi Kota, MD?
Apply for one of the trials that Vamsi Kota, MD is conducting.
What is the office address of Vamsi Kota, MD?
The office of Vamsi Kota, MD is located at: Augusta University Medical Center, Augusta, Georgia 30912 United States. This is the address for their practice at the Augusta University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.